Neoplasms Clinical Trials in Grand Rapids, Michigan

5 studies are recruiting for neoplasms in Grand Rapids, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

   The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D[s]) and optimal dosing schedule(s) of JNJ-88549968 in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s) in part 2 (Cohort Expansion). For U.S. sites: the purpose of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Start Midwest, Grand Rapids, Michigan

   Locations

   41 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06150157 on ClinicalTrials.gov

2. A Study of JNJ-87890387 for Advanced Solid Tumors

   The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Start Midwest, Grand Rapids, Michigan

   Locations

   6 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06178614 on ClinicalTrials.gov

3. Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

   This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site 04, Grand Rapids, Michigan

   Locations

   5 in total

   Run by

   Corcept Therapeutics

   See if you can join NCT07276373 on ClinicalTrials.gov

4. A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

   The purpose of the study is to check how safe and well-tolerated [18F]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   BAMF Health Inc., Grand Rapids, Michigan

   Locations

   6 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07258836 on ClinicalTrials.gov

5. A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

   The goal of this study is to assess the safety and tolerability of Mocertatug Rezetecan . The study will also see how the levels of Mo-Rez change over time at different dose amount

   Stage

   Phase 1

   Ages

   18 and older

   Site

   GSK Investigational Site, Grand Rapids, Michigan

   Locations

   65 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06431594 on ClinicalTrials.gov